A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome

The FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutation in acute myeloid leukemia (AML) is associated with poor prognosis. We hypothesized that quizartinib, a selective and potent FLT3 inhibitor, with azacitidine (AZA) or low-dose cytarabine (LDAC) might improve the outcomes i...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Haematologica
Autors principals: Swaminathan, Mahesh, Kantarjian, Hagop M., Levis, Mark, Guerra, Veronica, Borthakur, Gautam, Alvarado, Yesid, DiNardo, Courtney D., Kadia, Tapan, Garcia-Manero, Guillermo, Ohanian, Maro, Daver, Naval, Konopleva, Marina, Pemmaraju, Naveen, Ferrajol, Alessandra, Andreeff, Michael, Jain, Nitin, Estrov, Zeev, Jabbour, Elias J., Wierda, William G., Pierce, Sherry, Pinsoy, Maria Rhona, Xiao, Lianchun, Ravandi, Farhad, Cortes, Jorge E.
Format: Artigo
Idioma:Inglês
Publicat: Fondazione Ferrata Storti 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8327731/
https://ncbi.nlm.nih.gov/pubmed/33853292
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2020.263392
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars